HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical

Alpha Tau Medical Ltd. (NASDAQ:DRTS) – Research analysts at HC Wainwright decreased their FY2025 EPS estimates for shares of Alpha Tau Medical in a research note issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.53) for the year, down from their prior estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.45) per share.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13).

Alpha Tau Medical Stock Down 0.8 %

DRTS stock opened at $2.60 on Wednesday. Alpha Tau Medical has a fifty-two week low of $1.75 and a fifty-two week high of $4.39. The firm’s 50-day simple moving average is $3.23 and its 200 day simple moving average is $2.79. The stock has a market cap of $181.80 million, a PE ratio of -6.05 and a beta of 0.87.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently bought and sold shares of the stock. Levin Capital Strategies L.P. increased its stake in Alpha Tau Medical by 2.3% during the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after buying an additional 7,189 shares during the period. Northern Trust Corp increased its stake in Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after buying an additional 25,770 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after buying an additional 26,800 shares during the period. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.